News End of the line for MSD's TIGIT, LAG-3 cancer drugs MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.
News More bad news for TIGIT as MSD stops another trial Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.
News MSD has another TIGIT programme setback A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face